TL;DR: In published research, retatrutide is a triple GIP/GLP-1/glucagon receptor agonist and tirzepatide is a dual GIP/GLP-1 agonist. Tirzepatide has completed large phase 3 obesity trials; retatrutide reported strong phase 2 results and only topline phase 3 data in 2026. Retatrutide remains earlier-stage and investigational.
The core difference: dual vs. triple receptor agonism
Both molecules belong to the incretin-mimetic class, but they engage a different number of receptors. Tirzepatide activates two: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Retatrutide adds a third target, the glucagon (GCG) receptor, making it a triple agonist.
That extra glucagon arm is the headline mechanistic distinction studied in the literature. Glucagon-receptor activity is associated in preclinical and clinical research with increased energy expenditure and effects on hepatic lipid handling, layered on top of the appetite- and glucose-related effects shared with GLP-1 and GIP agonism. Whether this translates into a durable, safe advantage in humans is exactly what ongoing trials are designed to answer.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor targets | GIP + GLP-1 + glucagon (triple) | GIP + GLP-1 (dual) |
| Developer code | LY3437943 | LY3298176 |
| Highest published trial stage | Phase 3 (2026 topline) | Phase 3 completed and published |
| Key obesity dataset | Phase 2, NEJM 2023 | SURMOUNT-1, NEJM 2022 |
| Dosing frequency studied | Once weekly (subcutaneous) | Once weekly (subcutaneous) |
| Regulatory status (mid-2026) | Investigational, not approved | Approved in several markets for the listed indications |
You can review individual reference profiles for retatrutide 10mg and tirzepatide 10mg, and compare both against the GLP-1-only benchmark, semaglutide 10mg.
What the research shows
The evidence bases are not at the same maturity, and any honest comparison has to say so.
Tirzepatide: mature phase 3 human data
Tirzepatide’s obesity evidence is anchored by SURMOUNT-1 (Jastreboff et al., NEJM 2022), a 72-week phase 3 randomized controlled trial. Participants receiving tirzepatide achieved mean body-weight reductions of 16.0%, 21.4%, and 22.5% at the 5 mg, 10 mg, and 15 mg weekly doses, versus 2.4% for placebo. A later head-to-head trial, SURMOUNT-5 (Aronne et al., NEJM 2025), randomized 751 adults with obesity and reported 20.2% weight loss with tirzepatide versus 13.7% with semaglutide over 72 weeks — the largest efficacy gap yet reported between two approved anti-obesity agents in a direct comparison.
Retatrutide: strong phase 2, early phase 3
Retatrutide’s most-cited human dataset is a phase 2 trial (Jastreboff et al., NEJM 2023) in 338 adults with obesity. At 48 weeks, mean weight reductions were 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg), and 24.2% (12 mg), against 2.1% for placebo. In 2026, the sponsor reported topline phase 3 (TRIUMPH-1) results — roughly 28.3% mean weight reduction at the 12 mg dose over 80 weeks in about 2,339 participants — but as of mid-2026 the full peer-reviewed phase 3 manuscript and any regulatory approval were still pending.
The practical takeaway: tirzepatide’s efficacy and safety profile has been characterized across multiple completed, published phase 3 trials, whereas retatrutide’s phase 3 record so far rests largely on a company press release and one phase 2 paper. Numerically the phase 2 retatrutide figures look competitive-to-favorable, but cross-trial numbers are not a substitute for a direct randomized comparison — no head-to-head retatrutide-vs-tirzepatide trial has been published.
Different trials, durations, and doses — not a head-to-head comparison.
Safety and tolerability signals in the literature
In the trials above, the dominant adverse events for both molecules were gastrointestinal — nausea, diarrhea, vomiting, constipation — mostly mild-to-moderate and concentrated during dose escalation. The retatrutide phase 2 investigators reported a safety and side-effect profile broadly similar to that seen with GLP-1 and GIP/GLP-1 agonists, plus dose-dependent increases in heart rate that warrant longer-term study. Because retatrutide’s glucagon activity is novel at this scale, its long-term cardiovascular, hepatic, and glycemic safety picture is still being assembled through ongoing phase 3 work.
None of this constitutes guidance for use. These are research observations from controlled trials, not instructions.
How to think about “newer” vs. “more proven”
It is tempting to read a higher phase 2 percentage as “retatrutide wins.” A more careful reading of the research is:
- Different trial stages mean different levels of certainty. Phase 2 estimates commonly shift once larger, longer phase 3 populations are studied.
- Different trial designs (duration, dose titration, population, dropout handling) make raw percentages only loosely comparable across studies.
- Approval status differs. Tirzepatide has completed the regulatory bar in multiple markets for its indications; retatrutide had not, as of mid-2026.
For readers tracking the reference-material and cost landscape rather than clinical use, the price index tracks how these compounds are listed across suppliers for research purposes.
Frequently Asked Questions
Is retatrutide stronger than tirzepatide?
Cross-trial numbers suggest retatrutide’s phase 2 and topline phase 3 weight-loss figures are competitive with or numerically higher than tirzepatide’s phase 3 results. However, no head-to-head trial has compared them directly, so “stronger” is not something the current literature can confirm.
What is the mechanistic difference between them?
Tirzepatide is a dual agonist at the GIP and GLP-1 receptors. Retatrutide adds a third target, the glucagon receptor, making it a triple agonist. That glucagon arm is studied for effects on energy expenditure and hepatic lipid metabolism beyond the shared GIP/GLP-1 actions.
Is retatrutide approved anywhere?
As of mid-2026, retatrutide was investigational and not approved by major regulators. Phase 3 (TRIUMPH) trials reported topline results in 2026, with a regulatory filing anticipated but not yet completed. Tirzepatide, by contrast, has completed and published phase 3 obesity trials.
How do they compare with semaglutide?
Semaglutide is a GLP-1-only agonist. In SURMOUNT-5 (NEJM 2025), tirzepatide produced greater weight loss than semaglutide (20.2% vs. 13.7%) over 72 weeks. Retatrutide has not been compared head-to-head with semaglutide in a published trial.
Why is retatrutide called “earlier-stage”?
Because its strongest published human dataset is a single phase 2 trial (NEJM 2023). The 2026 phase 3 numbers came from a sponsor press release, with the full peer-reviewed manuscript and any approval still pending — a lower evidentiary bar than tirzepatide’s multiple completed phase 3 publications.
Are these compounds interchangeable in research contexts?
No. They are structurally distinct molecules with different receptor pharmacology, different trial evidence, and different regulatory status. They should be treated as separate research reference materials, not substitutes for one another.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2025;392(20):1892-1904.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial. The Lancet. 2023;402(10401):529-544.
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30(7):2037-2048.
This article is provided for educational and research-reference purposes only. It is not medical advice, and nothing here is a therapeutic recommendation or a human dosing instruction. The compounds discussed are research materials; retatrutide is investigational and not approved for general use. Always consult qualified professionals and applicable regulations.